Vergentan

Quick links to important sections

Vergentan

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vergentan

Property Description
Active Ingredient Alizapride (INN)
Form Tablets; Solution for Injection
Pharmacological Class Antiemetic; Prokinetic Agent
General Purpose Management of nausea and vomiting
Origin Synthetic organic compound

Vergentan is a prescription-only pharmaceutical product utilizing the active ingredient Alizapride. It is a trade name for this established antiemetic agent, which is used to manage sensations of sickness and the vomiting reflex. Structurally classified as a substituted benzamide derivative, its primary purpose is to provide relief by regulating both the central nervous system signals and the digestive processes that control these symptoms.


What Type of Medicine is Vergentan (Alizapride)?

Vergentan is classified as an antiemetic and a propulsive agent, or prokinetic, indicating its dual capacity to suppress the central urge to vomit and stimulate coordinated gut movement. The active substance is Alizapride, a single-ingredient compound designated as the International Nonproprietary Name (INN). Alizapride is a dopamine D2 receptor antagonist with combined prokinetic and antiemetic effects. This means the compound works by blocking specific nerve signals responsible for triggering sickness, which is particularly useful in situations requiring rapid and comprehensive symptom control, such as post-operative care.


Composition and Available Preparation Types

The core composition of Vergentan centers exclusively on the active ingredient Alizapride, often formulated as the hydrochloride salt, combined with standard pharmaceutical excipients. This single-ingredient medication is manufactured in high-level dosage forms to allow for flexible delivery, including tablets for oral intake and a solution for injection suitable for parenteral (intramuscular or intravenous) administration. The availability of these distinct delivery methods allows healthcare providers to select the most suitable route of administration based on the patient's immediate needs.


General Purpose and High-Level Function

The general purpose of Vergentan is to prevent the central nervous system from initiating the vomiting reflex and to support healthy digestive function. It achieves this by blocking specific D2 receptors in the brain's chemoreceptor trigger zone (CTZ), which interrupts the chemical signals that cause nausea. Simultaneously, its prokinetic action enhances the natural, wave-like movements, known as peristalsis, of the upper gastrointestinal tract, ensuring better coordination of the digestive system.

What side effects are possible with Vergentan?

Possible Side Effects and Safety Information

The safety profile of Vergentan (Alizapride), as documented in official regulatory sources, defines potential adverse reactions primarily affecting the nervous system, movement, and the gastrointestinal tract. Side effects are classified based on their frequency and the physiological system involved.

Classification of Adverse Reactions

The most frequently reported side effects are categorized within Nervous System Disorders and Gastrointestinal Disorders. Common reactions generally documented in clinical use include drowsiness or sedation, headache, dizziness, and minor gastrointestinal changes such as diarrhea or constipation.

Documented Serious Safety Concerns

The official labeling notes the risk of Extrapyramidal Motor Disorders (EPS). These serious adverse reactions, which include conditions such as acute dystonia and generalized dyskinesia, reflect the medication's pharmacological class and have been reported, particularly at higher dosages. Orthostatic hypotension (low blood pressure upon standing) is also a documented vascular side effect, especially when higher doses are administered. Prolonged treatment carries a cautionary note regarding the risk of late persistent dyskinesia.

Mandatory Safety Constraints

Specific safety restrictions are mandated by regulatory authorities. Vergentan is generally contraindicated in patients with a known history of dyskinesia induced by neuroleptics and in those with pheochromocytoma (a tumor of the adrenal gland). Due to the potential to lower the seizure threshold, caution is advised for patients with epilepsy. Use during pregnancy and lactation is generally discouraged as a precautionary measure, and older adults are noted as a population with increased risk for certain persistent movement disorders during prolonged therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Vergentan is the brand name for the active ingredient rizatriptan. All information regarding overdose is based on official regulatory labeling for rizatriptan products.

Documented Overdose Presentations

Overdose with this medication may be associated with symptoms affecting the central nervous system. In clinical studies involving healthy adult subjects who received doses significantly higher than the recommended maximum, the reported manifestations included dizziness and somnolence (drowsiness). There have also been reports of syncope (fainting), vomiting, and disturbances in heart rhythm, such as bradycardia (slow heart rate), in individuals who received excessive amounts.

Required Emergency Actions

Urgent medical attention is required for any suspected overdose. The regulatory labeling explicitly states that patients must be managed with general supportive measures. Due to the potential for serious events, clinical and electrocardiographic monitoring of the patient should be continued for a minimum of 12 hours, even if the patient shows no immediate symptoms of overdose. The effect of dialysis (hemodialysis or peritoneal dialysis) on removing the drug from the body is currently unknown, meaning these procedures may not be effective in treating the overdose.

Therapeutic Uses of Vergentan

What Vergentan Treats: Main Uses and Benefits

Vergentan (Alizapride) is an antiemetic medication that is commonly used to help with the management of acute and disruptive symptom patterns related to sickness and vomiting. Alizapride may be part of symptomatic management for various manifestations of nausea and vomiting, including those related to the postoperative period. The medication is used to provide supportive relief that may help patients cope more steadily with difficult episodes of sickness and contributes to easing the overall symptom load.

The medication may be applied in addressing symptoms across therapeutic domains, including sickness associated with chemotherapy (CINV), radiation therapy (RINV), and the postoperative recovery period (PONV). It is also relevant for severe, persistent nausea, symptoms related to impaired gastric motility, and emesis secondary to systemic conditions like uremia or migraine.

“The medication is used to provide supportive relief that may help patients cope more steadily with difficult episodes of sickness and contributes to easing the overall symptom load.”

Quick Fact: Relief for Acute Nausea and Vomiting

Vergentan is applied when symptoms create noticeable physiological strain and when short-term symptomatic assistance is needed for managing established emesis, contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vergentan?

Eligibility for Vergentan (Alizapride) is strictly defined by regulatory documents, which outline mandatory contraindications and necessary restrictions for specific populations.


Official Eligibility Profile

Category Regulatory Status
Absolute Contraindications Prohibited in patients with known hypersensitivity to Alizapride, pre-existing conditions leading to gastrointestinal perforation or hemorrhage (e.g., obstruction), and those with pheochromocytoma.
Conditional Use Populations Use requires special caution or dose modification for patients with a history of seizure disorders, impaired renal function, and older adults due to potential neurological sensitivity.
Reproductive Status Not Recommended during pregnancy and lactation, as safety in these populations is not fully established by regulatory authorities.
Age-Group Eligibility Authorized for the adult population. Eligibility for pediatric patients is conditional and often restricted to specific clinical indications, requiring specialized administration guidelines.

The medicine is reserved for the general adult population and specific groups whose condition allows for conditional use under the documented label constraints.

What should I know about interactions with other medicines?

Vergentan’s active component, alizapride, is a dopamine antagonist. This pharmacological action underlies its key documented interactions, which primarily involve other medicinal products that also affect the central nervous system or modulate dopamine activity. Co-administration may necessitate close clinical observation and potential adjustments to the treatment regimen.

Potential Drug-Drug Interactions

Interaction Classification Interacting Agents (Product Classes/Examples)
Increased Sedation Central nervous system (CNS) depressants, including alcohol, opioids, and benzodiazepines
Decreased Efficacy Dopamine agonists such as levodopa and bromocriptine
Increased Adverse Effect Risk Other agents that may induce extrapyramidal symptoms, such as certain antipsychotics

Interaction Context and Restrictions

Concurrent use with CNS depressants or alcohol can enhance the sedative effect, which is classified as clinically significant. The antiemetic effect of Vergentan may be reduced when combined with dopamine agonists; therefore, this combination is generally discouraged. Due to the potential for severe adverse reactions affecting motor function, caution is required when combining with other medications known to increase the risk of extrapyramidal symptoms. This interaction profile requires careful evaluation of all concomitant treatments.

Mechanism of Action

Vergentan (alizapride) functions as a substituted benzamide that acts primarily through antagonism of the dopamine D2 receptor. This interaction occurs at two main sites: centrally within the Chemoreceptor Trigger Zone (CTZ) and peripherally in the enteric nervous system of the gastrointestinal tract.

In the CTZ of the medulla, Vergentan occupies and blocks the D2 receptors. Since dopamine acts as an excitatory neurotransmitter in this area, its competitive inhibition by Vergentan modulates the afferent signaling cascade that initiates the vomiting reflex.

Peripherally, the compound also influences gastrointestinal motility by enhancing the release of acetylcholine (ACh) from the enteric neurons. The resulting increase in ACh concentration promotes sustained peristaltic contractions, primarily in the esophagus and stomach, which facilitates the forward propagation of luminal contents. This dual neurochemical and motor modulation constitutes the complete pharmacodynamic profile.

Dosage and Administration Information

How to Use Vergentan

Vergentan (Alizapride) is administered based on instructions that define the route, dose, and duration of use. The medicine is primarily intended for short-term intervention, following defined parameters for its application.


Administration Guidelines

Entity Detail
Route of Administration The medication is approved for Oral administration (via tablets) and Parenteral administration, including Intramuscular (IM) and Intravenous (IV) injection.
Standard Dosing Oral single doses typically range from 50 mg to 100 mg. Parenteral administration, often used for acute needs, may involve initial doses up to 100 mg (50 mg/mL solution).
Frequency Oral doses are usually administered in divided daily doses, such as two to three times daily. Parenteral administration can be scheduled in intervals, such as a pre-treatment dose followed by doses repeated every 8 hours in some acute regimens.
Duration Constraint Continuous treatment is generally specified for short-term use and should typically not exceed seven consecutive days.
Administration Conditions IV administration must be performed slowly. Oral tablets are generally taken with a glass of water.

Population-Specific Use

Labeling requires a dose reduction for patients with severe kidney failure due to the primary route of elimination being renal. The parenteral route is primarily reserved for acute management under specialist supervision.

These instructions establish the boundaries for using the medicine, defining the delivery method, quantity, and time constraint for the course of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vergentan

This overview summarizes what the research has studied, what study characteristics have been observed, and what remains uncertain, without providing any clinical advice or interpretation. The evidence base is built upon official scientific research, including controlled clinical trials and systematic reviews.


Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Vergentan was evaluated in research exploring how symptoms change over time during conditions associated with acute episodes following cancer treatment. This evidence base includes Randomized Controlled Trials (RCTs) where the compound was observed in adult cancer patients. Studies monitored outcomes related to physical discomfort, covering both the immediate acute phase (the first 24 hours) and the delayed phase (up to 5 days) following chemotherapy. Findings describe data show patterns related to symptom intensity observed in studies. Some trials described its evaluation as an agent that was studied following initial preventative measures. Certainty remains low regarding its specific role compared to current first-line agents, and comparative evidence is lacking for certain modern antiemetic regimens.


Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Vergentan was studied for conditions characterized by episodic manifestations following surgery. This research included RCTs and double-blind, placebo-controlled studies, which was observed in adult patients undergoing various surgical procedures, including those classified as high-risk for PONV. Researchers examined outcomes describing acute changes in the incidence of nausea and vomiting, alongside the need for supplemental study medication. Follow-up durations were limited, mainly focusing on immediate recovery and typically concluding after 24 hours post-surgery. As a result, long-term effects are not fully established.


Evidence in Special Populations and Research Gaps

Research has explored the use of Vergentan in specific groups, such as those categorized as high-risk for PONV. However, data for certain groups remain insufficient. While some studies included younger adults, dedicated research to establish specific patterns in the pediatric population is limited. Research so far indicates that clinical trials have primarily focused on short-term outcomes. Evidence highlights what is known—and what is still uncertain—with comparative evidence being limited for current standard-of-care agents.

Key Studies & References

  1. Alizapride: IUPHAR/BPS Guide to PHARMACOLOGY entry (Dopamine D2 Receptor Antagonist)

Frequently Asked Questions (FAQ)

Common questions about Vergentan (FAQ)

Q: Is it safe to take pain relievers like ibuprofen or Tylenol with Vergentan?

A: Official product information advises caution when combining Vergentan with other medications, particularly those that affect the central nervous system (CNS). While many common non-opioid pain relievers are not typically CNS depressants, information emphasizes the importance of a patient's healthcare professional reviewing all concurrent treatments, including non-prescription pain relievers.


Q: Is there a food or drink I need to avoid while on Vergentan?

A: Official drug documents advise that alcohol should be avoided while taking Vergentan. This is because alcohol can increase the risk of drowsiness and sedation caused by the medication. No specific solid foods are commonly listed as needing avoidance.


Q: Are there any long-term effects of taking Vergentan?

A: Vergentan is primarily intended for short-term use, but for prolonged treatment, regulatory documents include a cautionary note about the risk of late persistent dyskinesia. Dyskinesia is described as involuntary, erratic movements that may affect the body.


Q: Do I need to change my diet while taking Vergentan?

A: Official documentation advises that alcohol should not be consumed because it can increase the sedative effects of the medicine. Beyond avoiding alcohol, official information does not typically specify that a patient must follow a strict change in their diet.


Q: Can Vergentan affect my sleep?

A: Official labeling lists drowsiness and sedation as common side effects of Vergentan, which indicates the medication may interfere with normal sleep patterns or alertness. Any significant changes in sleep patterns or excessive tiredness are important details for a patient's healthcare professional.


Q: Does Vergentan interact with any common vitamins or supplements?

A: Regulatory warnings typically focus on prescription drug classes that interact, but also include a general warning to notify a healthcare provider about all concomitant treatments. This includes common vitamins, herbal remedies, and supplements, as these can sometimes affect how the body processes the medicine.


Q: Can Vergentan be used to treat other conditions besides its main use?

A: According to the official product information and regulatory approvals, Vergentan is officially indicated and authorized only for the treatment of nausea and vomiting related to specific circumstances, such as chemotherapy or post-operative care.


Q: What is the molecular structure of Vergentan? (Factual, high-level query)

A: The active ingredient in Vergentan, Alizapride, is classified as a substituted benzamide derivative. This refers to its specific chemical arrangement, which gives it its ability to block dopamine receptors in the body.


Q: Does Vergentan interact with herbal supplements like St. John's Wort?

A: Drug labels mandate caution when combining Vergentan with products that affect the central nervous system. Information highlights the importance of a patient's healthcare provider being aware of all supplements, including herbal products like St. John's Wort, before treatment.


Q: Will Vergentan affect my ability to drive or operate machinery?

A: Yes. Official labeling explicitly warns patients about the risk of drowsiness and dizziness with this medicine. Regulatory documents state that patients affected by these symptoms should avoid operating machinery or driving.


Q: Does taking Vergentan mean I will eventually be able to stop taking it?

A: Yes, treatment with Vergentan is typically intended to be temporary. Official administration guidelines usually specify that treatment is generally restricted to short-term use, often not exceeding a specified number of consecutive days.


Q: Does Vergentan cause weight gain?

A: The comprehensive list of documented adverse reactions (side effects) must be consulted for this information. If weight gain is not explicitly listed in the official regulatory data, it is not a documented side effect according to the authorized product information.


Q: How long does it typically take for Vergentan to start working?

A: Regulatory documents describe the drug’s pharmacokinetics, which includes the time it takes for the concentration of the active ingredient to reach its peak in the bloodstream. This information provides an indirect indication of the expected onset of action.


Q: What happens if I miss a dose of Vergentan?

A: Official dosing guidelines typically contain instructions for managing a missed dose. This information specifies whether to take the dose as soon as remembered or skip it and continue with the regular schedule, depending on the elapsed time.


Q: Can I drink coffee or caffeine while taking Vergentan?

A: Official product information is the primary source for interaction warnings. While alcohol is specifically prohibited due to increased sedation, the label should be checked for any general warnings regarding substances that affect the central nervous system or blood pressure, which may include caffeine.


Q: Does Vergentan have a risk of dependence or addiction?

A: Regulatory documents address the potential for abuse and dependence for all approved medicines. If Vergentan is not classified as a controlled substance by national drug scheduling lists, the potential risk for dependence is generally considered low according to official sources.


Q: Is Vergentan safe to take if I have high blood pressure?

A: While high blood pressure itself may not be a contraindication, the official label warns of a side effect called orthostatic hypotension. This is a drop in blood pressure when moving to a standing position, which may be relevant for patients with existing blood pressure issues.


Q: Can I take Vergentan if I have a liver problem?

A: Official regulatory documents specify whether a patient with hepatic impairment (liver problems) needs a dose adjustment or if a liver problem is a listed contraindication. This information clarifies if special caution is necessary.


Q: How long does the effect of one dose of Vergentan last?

A: The duration of the drug’s presence in the body is often described by its elimination half-life (t1/2) in official documents. This key pharmacokinetic parameter helps determine how frequently the medication is typically administered.


Q: Does Vergentan cause hair loss?

A: The official list of documented adverse reactions must be consulted. If hair loss is not explicitly included in the drug's safety profile as defined by regulatory data, it is not a documented side effect according to the authorized product information.


Q: Can I stop taking Vergentan suddenly?

A: Official drug labels contain clear instructions on how the medication should be discontinued. Because Vergentan is a central nervous system-acting drug, it is important to follow the labeled guidelines for cessation, which may involve a gradual reduction.


Q: What should I do if the side effects of Vergentan are bothersome?

A: Official documents describe the necessity for patients to report adverse effects to a healthcare professional. Information regarding serious or bothersome reactions highlights the importance of immediate communication with the patient's medical team or a regulatory monitoring program.


Q: Does Vergentan have a black box warning?

A: Official FDA documents will explicitly state whether the medication has a Boxed Warning (colloquially called a Black Box Warning). This warning is reserved for serious safety risks associated with the drug and, if applicable, describes the nature of that risk.


Q: Can Vergentan be crushed or split?

A: Administration guidelines and the formulation section of official documents specify whether the tablets can be crushed, split, or chewed. It is essential to follow these instructions, as altering the form can affect how the medicine works or is absorbed.


Q: Is Vergentan a controlled substance?

A: Official government drug scheduling lists confirm whether the active ingredient is classified under a specific schedule due to potential for abuse or dependence. These lists determine if Vergentan is designated as a controlled substance.


Q: Can Vergentan affect my mood?

A: The regulatory list of adverse reactions is the only authorized source for side effects. Any adverse mental health or mood effects (such as agitation, anxiety, or depression) would be listed in this section if they were reported in clinical trials or post-marketing surveillance.


Q: Where can I find the official package insert for Vergentan?

A: The complete, official product information, including the package insert or Summary of Product Characteristics (SmPC), is available through government sources. Examples include the FDA DailyMed database or the public information sections of regulatory agencies.


Q: Are there different brands of Vergentan?

A: National drug registries and regulatory databases list all approved trade names containing the active ingredient, Alizapride. Consulting these sources confirms the existence of different registered brands beyond the name Vergentan.


Q: What is the half-life of Vergentan? (Purely factual query)

A: Official drug information contains key pharmacokinetic parameters, including the drug's elimination half-life (t1/2). This figure represents the time it takes for the concentration of the medication in the body to be reduced by half.

How should Vergentan be stored and disposed of?

How to Store and Dispose of Vergentan

Official regulatory guidelines strictly define the conditions under which Vergentan must be stored and disposed of to maintain its stability and effectiveness.

Storage Requirement Official Label Instruction
Temperature Store at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF).
Environment Keep the product in its original, tightly closed container. Protect from moisture and excessive heat; do not freeze.
Safety Keep Vergentan out of the sight and reach of children.
Disposal Do not discard the medicine by flushing it down a toilet or pouring it down a drain. Use an official drug take-back program or follow local governmental guidelines for disposal of unused or expired medications.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vergentan found in:

A-Z Index: